Publicly Listed Company Artelo Launches Solana Reserve Asset Strategy
According to ChainCatcher, citing GlobeNewswire, clinical-stage pharmaceutical company Artelo Biosciences (NASDAQ: ARTL) has announced the completion of a $9.475 million private placement, which will be used to launch a digital asset reserve strategy centered on Solana (SOL). The company has become the first publicly listed pharmaceutical firm to include SOL as a reserve asset.
This private placement involves the issuance of common stock (or prepaid warrants) at a price of $10.45 per share, as well as two tranches of three-year warrants with exercise prices of $10.20 and $50, respectively. The transaction is expected to be completed by August 5, 2025.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A Bitcoin whale deposits 20 million USDC into HyperLiquid and opens a 6x leveraged ETH long position
Walrus Airdrops NFTs to Staking Users, WAL Tokens Available for Claim
Andrew Tate, a KOL with millions of followers, shorts YZY with a position size of $175,000
"Big Brother Machi" Long Position Unrealized Loss Narrows to $8.4 Million
Trending news
MoreCrypto prices
More
